| 20047614 |
Mannheimer EG, Quintanilha LF, Carvalho AB, Paredes BD, Goncalves de Carvalho F, Takyia CM, Resende CM, Ferreira da Motta Rezende G, Carlos Campos de Carvalho A, Schanaider A, Coeli Dos Santos Goldenberg R: Bone marrow cells obtained from cirrhotic rats do not improve function or reduce fibrosis in a chronic liver disease model. Clin Transplant. 2009 Dec 28.
Mannheimer EG, Quintanilha LF, Carvalho AB, Paredes BD, Carvalho FG, Takyia CM, Resende CMC, Rezende GFM, Campos de Carvalho AC, Schanaider A, Goldenberg RCS. Bone marrow cells obtained from cirrhotic rats do not improve function or reduce fibrosis in a chronic liver disease model. Clin Transplant 2009 DOI: 10.1111/j.1399-0012.2009.01191.x. (c) 2009 John Wiley & Sons A/S. Abstract: Background: The objective of this study was to evaluate the therapeutic potential of bone marrow cells (BMCs) obtained from cirrhotic donors in a model of chronic liver disease. Methods: Chronic liver injury was induced in female Wistar rats by the association of an alcoholic diet with intraperitoneal injections of carbon tetrachloride. BMCs obtained from cirrhotic donors or placebo were injected through the portal vein. Blood analysis of alanine aminotransferase (ALT) and albumin levels, ultrasound assessment including the measurement of the portal vein diameter (PVD) and liver echogenicity, histologic evaluation with hematoxylin and eosin and Sirius red staining, and quantification of collagen deposition were performed. Results: ALT and albumin blood levels showed no significant differences between the experimental groups two months after injection. Additionally, no significant variation in PVD and liver echogenicity was found. Histological analysis also showed no significant variation in collagen deposition two months after placebo or BMC injection. Conclusion: This study suggests that, even though BMC therapy using cells from healthy donors has previously shown to be effective, this is not the case when BMCs are obtained from cirrhotic animals. This result has major clinical implications when considering the use of autologous BMCs from patients with chronic liver diseases. |
1(0,0,0,1) |